Recent advances in KRAS research have led to the development of more potent and selective inhibitors. The FDA's approval of Sotorasib for non-small cell lung cancer with the KRAS G12C mutation marks a significant milestone. Ongoing clinical trials are exploring novel inhibitors and combination therapies, showing promising results in improving patient outcomes.
